Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia.
To review the current state of molecular and genetic profiling of acute myeloid leukemia (AML) and its implications. Peer-reviewed journal articles. Significant advances in the understanding of the pathology of acute myeloid leukemia have led to refined risk stratification of patients and application of novel targeted therapies based on genetic profiles. Minimal residual disease testing allows for highly sensitive disease surveillance that can be used to predict relapse and assess treatment response. Accurate prognostication and therapeutic decision-making for patients with acute myeloid leukemia is dependent on molecular profiling. Being knowledgeable of the implications of minimal residual disease testing is critical for patient-centered care.